Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tendocare is an over-the-counter oral nutraceutical supplement developed by Pharmed and manufactured by Crius Life Sciences. It is formulated as a combination tablet containing low-molecular-weight type I collagen peptides, sodium hyaluronate, chondroitin sulfate, and vitamin C (ascorbic acid). Tendocare is designed to support tendon health, joint function, and the regeneration of connective tissues. It is commonly used as a supportive therapy for tendinopathies (such as frozen shoulder, plantar fasciitis, and Achilles tendinopathy), joint pain, and osteoarthritis. The ingredients work synergistically: type I collagen peptides provide the structural building blocks for tendon repair; sodium hyaluronate and chondroitin sulfate support joint lubrication, hydration, and structural resilience; and vitamin C acts as an essential cofactor for collagen synthesis and provides antioxidant protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tendocare.